{"DataElement":{"publicId":"5608181","version":"1","preferredName":"Recurrent Disease First Treatment Planned Code","preferredDefinition":"A coded response as to the initial planned action or administration of therapeutic agents intended to alter or stop the pathologic process of a disease that has returned after a period of remission.","longName":"5608059v1.0:5608114v1.0","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"5608059","version":"1","preferredName":"Recurrent Disease First Therapeutic Procedure Plan","preferredDefinition":"The return of a disease after a period of remission._Preceding all others in time or space or degree._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._To devise, contrive, or form in design.","longName":"2678101v1.0:5608057v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"2678101","version":"1","preferredName":"Recurrent Disease","preferredDefinition":"The return of a disease after a period of remission.","longName":"C38155","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3978BEB6-6680-46F4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-06","endDate":null,"createdBy":"UMLLOADER_COCANUT","dateCreated":"2007-09-06","modifiedBy":"ONEDATA","dateModified":"2007-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5608057","version":"1","preferredName":"First Therapeutic Procedure Plan","preferredDefinition":"Preceding all others in time or space or degree.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:To devise, contrive, or form in design.","longName":"C25509:C49236:C25619","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Plan","conceptCode":"C25619","definition":"To devise, contrive, or form in design.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44097BAC-F46C-01E9-E053-F662850AFA49","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-12-19","modifiedBy":"ONEDATA","dateModified":"2016-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"44097BAC-F47D-01E9-E053-F662850AFA49","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-12-19","modifiedBy":"GARRIDOJ","dateModified":"2017-04-26","changeDescription":"Created for EA8143, 12/19/16 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5608114","version":"1","preferredName":"Recurrence Planned Therapy Type Code","preferredDefinition":"A symbol or combination of symbols which is assigned to the members of a collection.","longName":"5608114v1.0","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"3","valueDescription":"mTOR Inhibitor Targeted Therapy","ValueMeaning":{"publicId":"5608115","version":"1","preferredName":"mTOR Inhibitor Targeted Therapy","longName":"5608115","preferredDefinition":"Any substance that inhibits mammalian target of rapamycin (mTOR or FK506 binding protein 12-rapamycin associated protein 1 (FRAP1)), a serine/threonine protein kinase that is active in the control of cell growth, cell proliferation, and cell motility. Inhibition of mTOR can inhibit cell proliferation.: A type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells. Targeted therapy may have fewer side effects than other types of cancer treatments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"mTOR Inhibitor","conceptCode":"C2201","definition":"Any substance that inhibits mammalian target of rapamycin (mTOR or FK506 binding protein 12-rapamycin associated protein 1 (FRAP1)), a serine/threonine protein kinase that is active in the control of cell growth, cell proliferation, and cell motility. Inhibition of mTOR can inhibit cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Targeted Therapy","conceptCode":"C93352","definition":"A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4409C7DB-6F7C-7F83-E053-F662850A7BEF","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4409C7DB-6F97-7F83-E053-F662850A7BEF","beginDate":"2016-12-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-12-19","modifiedBy":"ONEDATA","dateModified":"2016-12-19","deletedIndicator":"No"},{"value":"2","valueDescription":"Immune System Cell Cycle Checkpoint Therapeutic Procedure","ValueMeaning":{"publicId":"5608117","version":"1","preferredName":"Immune System Cell Cycle Checkpoint Therapeutic Procedure","longName":"5608117","preferredDefinition":"The complex group of organs like thymus, spleen, tonsils, lymphatic system, hematopoetic system and cells like lymphocytes, granulocytes, monocytes and macrophages that defends the body against infection or disease. It consists of a complex interrelated cellular, molecular and genetic component.: Phases or points in the cell cycle at which a cell is prevented from progressing into the next phase of the cycle unless certain necessary and sufficient cellular conditions exist.  The checkpoints help maintain the proper order and timing of cell transition events, especially important for DNA replication and chromosome segregation.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune System","conceptCode":"C12735","definition":"The complex group of organs like thymus, spleen, tonsils, lymphatic system, hematopoetic system and cells like lymphocytes, granulocytes, monocytes and macrophages that defends the body against infection or disease. It consists of a complex interrelated cellular, molecular and genetic component.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cell Cycle Checkpoint","conceptCode":"C18689","definition":"Phases or points in the cell cycle at which a cell is prevented from progressing into the next phase of the cycle unless certain necessary and sufficient cellular conditions exist.  The checkpoints help maintain the proper order and timing of cell transition events, especially important for DNA replication and chromosome segregation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4409C7DB-6FA6-7F83-E053-F662850A7BEF","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4409C7DB-6FC1-7F83-E053-F662850A7BEF","beginDate":"2016-12-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-12-19","modifiedBy":"ONEDATA","dateModified":"2016-12-19","deletedIndicator":"No"},{"value":"1","valueDescription":"Vascular Endothelial Growth Factor Family Targeted Therapy","ValueMeaning":{"publicId":"5608119","version":"1","preferredName":"Vascular Endothelial Growth Factor Family Targeted Therapy","longName":"5608119","preferredDefinition":"A sub-family of the cysteine knot platelet-derived growth factor family. Members of the vascular endothelial growth factor (VEGF) family play a role in the promotion of embryonic vasculogenesis and the stimulation of angiogenesis during physiologic and pathologic processes.: A type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells. Targeted therapy may have fewer side effects than other types of cancer treatments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vascular Endothelial Growth Factor Family","conceptCode":"C129646","definition":"A sub-family of the cysteine knot platelet-derived growth factor family. Members of the vascular endothelial growth factor (VEGF) family play a role in the promotion of embryonic vasculogenesis and the stimulation of angiogenesis during physiologic and pathologic processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Targeted Therapy","conceptCode":"C93352","definition":"A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4409C7DB-6FCF-7F83-E053-F662850A7BEF","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4409C7DB-6FEA-7F83-E053-F662850A7BEF","beginDate":"2016-12-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-12-19","modifiedBy":"ONEDATA","dateModified":"2016-12-19","deletedIndicator":"No"},{"value":"88","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4409E3A0-32B6-18BA-E053-F662850AAF4D","beginDate":"2016-12-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-12-19","modifiedBy":"ONEDATA","dateModified":"2016-12-19","deletedIndicator":"No"},{"value":"4","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"2567129","version":"1","preferredName":"Radiation Therapy","longName":"2567129","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D346-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-10-21","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-10-21","modifiedBy":"KUMMEROA","dateModified":"2023-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"440A3F16-0088-4F80-E053-F662850A46A8","beginDate":"2016-12-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-12-19","modifiedBy":"ONEDATA","dateModified":"2016-12-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261841","version":"1","preferredName":"Code","preferredDefinition":"A system of numbered categories for representation of data.","longName":"C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FBB87F7A-6427-1AFC-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-13","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-07-13","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4409C7DB-6F4E-7F83-E053-F662850A7BEF","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-12-19","modifiedBy":"GARRIDOJ","dateModified":"2017-04-26","changeDescription":"Curated for EA8143, 12/19/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3852751","version":"1","longName":"Therapeutic","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"3314497","version":"1","longName":"Treatment","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"First planned treatment for t","type":"Preferred Question Text","description":"First planned treatment for this recurrence","url":null,"context":"ECOG-ACRIN"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"440A2456-60EF-3BCF-E053-F662850AA5D8","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-12-19","modifiedBy":"GARRIDOJ","dateModified":"2017-04-26","changeDescription":"Created for EA8143, 12/19/16 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}